Search

Graphical abstract Highlights • DA-9801 protects rat primary cortical neurons from hyperglycemia-induced cytotoxicity. • DA-9801 reduces reactive oxidative species caused by high glucose treatment. • Microarray analysis reveals that DA-9801 regulates gene expression. • Dioscin and Protodioscin, the major saponins of DA9801, protect cortical neurons. Abstract Neurodegenerative diseases, including Alzheimer's disease, are prevalent in diabetic patients. DA-9801 is a standardized extract of Dioscorea japonica Thunb. and Dioscorea nipponica Makino, which has been shown to reduce blood glucose levels and exert protective effects against diabetic peripheral neuropathy. Here, we aimed to investigate whether DA-9801 could protect hyperglycemia-induced central neuropathy and to elucidate the underlying mechanisms. DA-9801 protected rat cortical primary neurons against hyperglycemia-induced neurotoxicity by lowering the levels of reactive oxygen species. In addition, we identified the genes whose expression in high glucose-treated primary neurons was significantly altered by DA-9801 treatment. Moreover, the major saponins of DA-9801, dioscin and protodioscin, protected neurons from hyperglycemia-induced toxicity, suggesting that these may be the most important active neuroprotective components of DA-9801. Our results showed that DA-9801 protects neurons derived from the central nervous system and that it may be useful to treat and delay the development of neurodegenerative diseases in diabetic patients. [ABSTRACT FROM AUTHOR]

Abstract: Ethnopharmacological relevance: Dioscorea japonica Thunb. has been traditionally used to treat polyuria and diabetes in Korea. Aim of the study: We previously report the effects of Dioscorea japonica Thunb. extract on glucose control, NGF induction, and neuroprotection in a rodent diabetic model. Since the most potent fraction, DA-9801, was identified from a mixture of Dioscorea japonica Thunb. (DJ) and Dioscorea nipponica Makino (DN) following bioactivity-guided fractionation, here, we investigated the potential mechanism of the extract activity against diabetic peripheral neuropathy (DPN). Materials and methods: A 1:3 mixture of DJ and DN was extracted with ethanol (DA-9801) and further fractionated into an ethylacetate-soluble fraction (DA-9801E). Effects of these extracts on neurite outgrowth were measured in PC-12 cells and DRG neurons. Effects on cell viability and TrkA phosphorylation were evaluated in PC-12 cells. NGF induction effect was determined in primary Schwann cells as well as IMS32 cells (immortalized Schwann cells). Results: No cytotoxicity was observed in PC-12 cells at the concentration below 500μg/ml of either DA-9801 or DA-9801E. DA-9801 and DA-9801E at 100μg/ml and 10μg/ml, respectively, showed a significant effect on neurite outgrowth in PC-12 cells and DRG neurons in the presence of or absence a low concentration of NGF (2ng/ml). The Trk-A phosphorylation effect of DA9801 was confirmed in PC-12 cells. An NGF induction effect of these extracts was not detected in either IMS-32 cells, or primary Schwann cells. Conclusions: The NGF agonistic activity of DA-9801 and DA-9801E was demonstrated, which may contribute to their neuroprotective effect against DPN. Studies of the detailed mechanism of these extracts as well as identification of the active components are warranted for the development of an anti-DPN drug from DJ and DN. [Copyright &y& Elsevier]